首頁 > 市場調查報告書 > 醫療設備

導管

市場調查報告書

商品編碼

1289779

全球腫瘤消融市場 - 2023-2030年

Global Tumor Ablation Market - 2023-2030

出版日期: 2023年06月12日 | 出版商:

DataM Intelligence | 英文 195 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場概況

全球腫瘤消融市場在2022年達到7.974億美元，預計到2030年將見證有利可圖的成長，達到20.792億美元。在預測期內（2023-2030年），全球腫瘤消融市場預計將呈現13.1%的複合成長率。

腫瘤消融術可以在局部麻醉下進行，與傳統的癌症治療方法如手術、化療或放療相比，其副作用一般較少。腫瘤消融術被用於治療各種類型的癌症，包括肝癌、肺癌、腎癌和骨癌。

消融技術的進步、癌症發病率的增加、對微創手術需求的上升以及對腫瘤消融術比傳統癌症治療方法的好處認識的提高，是預計在預測期內推動腫瘤消融市場的一些因素。

市場動態

越來越多的FDA批准的腫瘤消融系統在預測期內推動了全球腫瘤消融市場的成長

2022年9月，世界領先的醫療技術公司之一史賽克公司宣布，其OptaBlate骨腫瘤消融系統（OptaBlate）獲得美國食品和藥物管理局的510（k）許可。 OptaBlate技術加入史賽克的介入性脊柱（IVS）產品組合，擴大了其在椎體增生和射頻消融方面的核心競爭力，完善了其對轉移性椎體骨折的治療方案組合。

此外，在2020年11月，克利夫蘭診所是世界上第一家使用美國食品和藥物管理局最近批准的消融技術的醫院，這種技術可以摧毀大型肝臟腫瘤。這種微創手術使用一根針連接到一個強大的150瓦的微波發生器。

與腫瘤消融系統相關的挑戰在預測期內阻礙了全球腫瘤消融市場的成長。

射頻消融（RFA）被推薦用於治療與轉移性脊柱病變相關的局部疼痛，但在開發新的RFA系統並將其用於兒科介入放射學方面仍存在挑戰。主要的挑戰是確保RFA系統在不同類型和位置的腫瘤中使用時是安全和有效的。

該系統創建的消融區應破壞整個腫瘤，同時避免對周圍健康組織的損害。此外，它應該準確地定位到腫瘤位置，這在身體的某些部位，如肝臟或肺部，尤其具有挑戰性。因此，上述因素預計將在預測期內阻礙市場的成長。

COVID-19影響分析

COVID-19的大流行對腫瘤消融市場產生了重大影響。在短期內，由於供應鏈的中斷，選擇性手術的延遲，以及病人到醫療機構就診的減少，市場受到了負面影響。這促使了對腫瘤消融手術和設備的需求下降。

此外，正在開發的新型消融技術，如微波和不可逆電穿孔，預計將推動市場的成長。這些較新的技術與傳統的射頻消融系統相比具有優勢，如更大的消融區和提高針對腫瘤的精度。

俄羅斯與烏克蘭的衝突分析

俄羅斯和烏克蘭的腫瘤消融市場可能會受到這兩個國家之間持續的政治緊張局勢的影響。在烏克蘭，衝突促使醫療系統陷入困境，這可能促使腫瘤消融手術的使用受到限制，並推遲採用較新的消融技術。

相比之下，俄羅斯對其醫療系統和採用較新的醫療技術進行了大量的投資。然而，對俄羅斯實施的經濟制裁和貿易限制限制了其獲得更新的消融技術和設備，影響了市場的成長。

Market Overview

The Global Tumor Ablation Market reached US$ 797.4 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 2,079.2 million by 2030. The global tumor ablation market is expected to exhibit a CAGR of 13.1% during the forecast period (2023-2030).

Tumor ablation procedure can be performed under local anesthesia and is generally associated with fewer side effects than traditional cancer treatments like surgery, chemotherapy, or radiation therapy. Tumor ablation is used to treat various types of cancer, including liver cancer, lung cancer, kidney cancer, and bone cancer.

Advancements in ablation technologies, increasing prevalence of cancer, rising demand for minimally invasive procedures, and growing awareness about the benefits of tumor ablation over traditional cancer treatments are some of the factors expected to drive the tumor ablation market over the forecast period.

Market Dynamics

The Increasing FDA Approvals of the Tumor Ablation System are Boosting the Global Tumor Ablation Market Growth During the Forecast Period

In September 2022, Stryker, one of the world's leading medical technology companies, announced that its OptaBlate bone tumor ablation system (OptaBlate) received 510(k) clearance from the U.S. Food and Drug Administration. The addition of the OptaBlate technology to Stryker's Interventional Spine (IVS) portfolio expands on its core competencies in vertebral augmentation and radiofrequency ablation and completes its portfolio of treatment options for metastatic vertebral body fractures.

Additionally, in November 2020, Cleveland Clinic was the first hospital in the world to use a recently FDA-approved ablation technology that can destroy large liver tumors. The minimally invasive procedure uses a single needle connected to a powerful 150-watt microwave generator

Challenges Associated with the Tumor Ablation System are Hampering the Growth of the Global Tumor Ablation Market in the Forecast Period.

Radiofrequency ablation (RFA) is recommended for treating localized pain associated with metastatic spinal lesions, but there are still challenges in developing new RFA systems and using them in pediatric interventional radiology. The main challenge is to ensure that the RFA system is safe and effective for use in different types and locations of tumors.

The ablation zone created by the system should destroy the entire tumor while avoiding damage to surrounding healthy tissue. Moreover, it should be targeted accurately to the tumor location, which is particularly challenging in certain areas of the body such as the liver or lung. Hence, the above factors are expected to hamper the market growth over the forecast period.

COVID-19 Impact Analysis

The COVID-19 pandemic has had a significant impact on the tumor ablation market. In the short term, the market has been negatively affected due to the disruption of supply chains, delays in elective surgeries, and a decrease in patient visits to healthcare facilities. This has resulted in a decline in the demand for tumor ablation procedures and devices.

Furthermore, the ongoing development of novel ablation technologies, such as microwave and irreversible electroporation, is expected to drive growth in the market. These newer technologies offer advantages over traditional radiofrequency ablation systems, such as a larger ablation zone and increased precision in targeting tumors.

Russia-Ukraine Conflict Analysis

The tumor ablation market in Russia and Ukraine may be impacted by the ongoing political tensions between the two countries. In Ukraine, the conflict has resulted in a struggling healthcare system, which may lead to limited access to tumor ablation procedures and delay the adoption of newer ablation technologies.

In contrast, Russia has invested heavily in its healthcare system and the adoption of newer medical technologies. However, the economic sanctions and trade restrictions imposed on Russia have limit its access to newer ablation technologies and devices, affecting the market's growth.

Segment Analysis

The global tumor ablation market is segmented based on technology, application, treatment mode, and region.

The Liver Cancer Segment is Expected to Hold a Dominant Position in the Market Over the Forecast Period.

The liver cancer segment accounted for the highest market stake accounting for approximately 1/3 of the vaccines market in 2022. Tumor ablation offers several advantages for treating liver cancer, including minimally invasive, high success rates, versatility, and preservation of liver function. Furthermore, the high incidence of liver cancer, favorable reimbursement policies, and advances in ablation technologies are the factors expected to hold the largest market share over the forecast period.

For instance, in the United States, reimbursement policies play a significant role in the use of tumor ablation for liver cancer. The Centers for Medicare and Medicaid Services (CMS) have established reimbursement codes for various tumor ablation procedures, including those for liver cancer. This helps to ensure that patients who undergo these procedures can receive reimbursement from their insurance providers.

Geographical Analysis

The Increasing Prevalence of Cancer, Advancements in Technology, the Availability of Reimbursement for Tumor Ablation Procedures, and the Presence of A Well-Established Healthcare Infrastructure Dominate the North American Region.

North America is expected to dominate the tumor ablation market, accounting for around 1/3rd of this market, with the U.S. being the major contributor.

For instance, newer MWA systems such as directional microwave ablation (DMWA) offer more precise control over the ablation zone, reducing the risk of damage to nearby healthy tissue. Similarly, newer RFA systems with multiple electrodes and real-time temperature monitoring have improved the accuracy and efficacy of the procedure. Cryoablation systems with improved freezing probes and real-time imaging have also become more widely available.

Moreover, the integration of imaging technologies such as ultrasound, computed tomography (CT), and magnetic resonance imaging (MRI) with ablation systems has further improved the accuracy and efficacy of tumor ablation procedures. These technological advancements have expanded the clinical applications of tumor ablation, making it a viable treatment option for a wide range of tumor types and locations.

Hence, owing to the above factors, the North American region is expected to hold the largest market share over the forecast period.

Competitive Landscape

The major global players in the market include: Medtronic, PLC., AngioDynamics Inc., Boston Scientific Corporation, Healthtronics, Inc., BVM Medical Limited, COMSOL Inc., Galil Medical, Inc., INTIO Inc., Misonix, Inc., NeuWave Medical, Inc., and SonaCare Medical, LLC among others.

Why Purchase the Report?

To visualize the global tumor ablation market segmentation based on the technology, application, treatment mode, and region and understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development.
Excel data sheet with numerous data points of tumor ablation market-level with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping available as Excel consisting of key products of all the major players.

The global tumor ablation market report would provide approximately 61 tables, 60 figures, and 195 pages.

Target Audience 2023

Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Technology
3.2. Snippet by Application
3.3. Snippet by Treatment Mode
3.4. Snippet by Region

4. Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. The increasing FDA approvals of the tumor ablation system
- 4.1.2. Restraints
  - 4.1.2.1. Challenges associated with the tumor ablation system
- 4.1.3. Opportunity
  - 4.1.3.1. Increasing collaborations and partnerships
- 4.1.4. Impact Analysis

5. Industry Analysis

5.1. Porter's 5 Forces Analysis
5.2. Supply Chain Analysis
5.3. Unmet Needs
5.4. Regulatory Analysis

6. COVID-19 Analysis

6.1. Analysis of COVID-19
- 6.1.1. Scenario Before COVID-19
- 6.1.2. Scenario During COVID-19
- 6.1.3. Scenario Post COVID-19
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturers' Strategic Initiatives
6.6. Conclusion

7. Russia-Ukraine War Analysis

8. By Technology

8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 8.1.2. Market Attractiveness Index, By Technology
8.2. Radiofrequency (Rf) Ablation*
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Microwave Ablation
8.4. Cryoablation
8.5. Other Technologies

9. By Application

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 9.1.2. Market Attractiveness Index, By Application
9.2. Liver Cancer*
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Lung Cancer
9.4. Kidney Cancer
9.5. Bone Metastasis
9.6. Others

10. By Treatment Mode

10.1. Introduction
- 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Mode
- 10.1.2. Market Attractiveness Index, By Treatment Mode
10.2. Surgical Ablation*
- 10.2.1. Introduction
- 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Laparoscopic Ablation
10.4. Percutaneous Ablation

11. By Region

11.1. Introduction
- 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 11.1.2. Market Attractiveness Index, By Region
11.2. North America
- 11.2.1. Introduction
- 11.2.2. Key Region-Specific Dynamics
- 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Mode
- 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 11.2.6.1. The U.S.
  - 11.2.6.2. Canada
  - 11.2.6.3. Mexico
11.3. Europe
- 11.3.1. Introduction
- 11.3.2. Key Region-Specific Dynamics
- 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Mode
- 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 11.3.6.1. Germany
  - 11.3.6.2. The U.K.
  - 11.3.6.3. France
  - 11.3.6.4. Italy
  - 11.3.6.5. Spain
  - 11.3.6.6. Rest of Europe
11.4. South America
- 11.4.1. Introduction
- 11.4.2. Key Region-Specific Dynamics
- 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Mode
- 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 11.4.6.1. Brazil
  - 11.4.6.2. Argentina
  - 11.4.6.3. Rest of South America
11.5. Asia-Pacific
- 11.5.1. Introduction
- 11.5.2. Key Region-Specific Dynamics
- 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Mode
- 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 11.5.6.1. China
  - 11.5.6.2. India
  - 11.5.6.3. Japan
  - 11.5.6.4. Australia
  - 11.5.6.5. Rest of Asia-Pacific
11.6. Middle East and Africa
- 11.6.1. Introduction
- 11.6.2. Key Region-Specific Dynamics
- 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Mode

12. Competitive Landscape

12.1. Competitive Scenario
12.2. Product Benchmarking
12.3. Company Share Analysis
12.4. Key Developments and Strategies

13. Company Profiles

13.1. Medtronic, PLC.*
- 13.1.1. Company Overview
- 13.1.2. Product Portfolio and Description
- 13.1.3. Financial Overview
- 13.1.4. Key Developments
13.2. AngioDynamics Inc.
13.3. Boston Scientific Corporation
13.4. Healthtronics, Inc.
13.5. BVM Medical Limited
13.6. COMSOL Inc.
13.7. Galil Medical, Inc.
13.8. INTIO Inc.
13.9. Misonix, Inc.
13.10. NeuWave Medical, Inc.
13.11. SonaCare Medical, LLC